@marklewismd Hey Mark, I’m having problems understanding the trial design of the nirogavestat study. Why wasn’t sorafenib on the control arm? Gounder was first author of the sorafenib study, which was published in 2018, the year before the nirogavestat st…
RT @DanielOlsonMD: @oncology_bg Placebos performed even better when compared to sorafenib: 20% ORR. Then consider all the drugs with purpor…
@oncology_bg Placebos performed even better when compared to sorafenib: 20% ORR. Then consider all the drugs with purported benefit for desmoids based only on single-arm studies. I wonder how much of that benefit is just spontaneous regression. https…
Data from "Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis (A091105)" has been published at https://t.co/T1OjBz4eTY! It contains 83 subjects with CT and MR imaging and supporting clinical data associated with https…